RSV, Merck
Merck's RSV Shot Cuts Infant Hospitalizations by Over 80% in Trial, Eyes 2025 Launch
Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage trial showed the treatment reduced RSV-related hospitalizations by over 80% and lower respiratory infections by 90% compared to a placebo in infants through five months.
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants. The seasonal shot met its primary goal in the mid-to-late stage trial,
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
Merck immune from antitrust claim that it misled FDA about mumps vaccine, court rules
Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...
BioSpace13h
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
BioWorld5h
Merck’s clesrovimab tortoise to Beyfortus in RSV race?
Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...
FiercePharma10d
Merck's Keytruda stages comeback in head and neck cancer with trial win in earlier-stage disease
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...
Merck (MRK) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
Pharmabiz3d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...